Clinical Trials Logo

Growth Hormone clinical trials

View clinical trials related to Growth Hormone.

Filter by:
  • None
  • Page 1

NCT ID: NCT06433375 Active, not recruiting - Periapical Diseases Clinical Trials

Evaluation of the Efficacy of Growth Hormone on Healing of Periapical Pathosis

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

This study aimed to evaluate the effect of growth hormone and non-surgical debulking of periapical tissues on healing of periapical pathosis

NCT ID: NCT05574894 Completed - Growth Hormone Clinical Trials

Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study

Start date: January 1, 2021
Phase: Phase 3
Study type: Interventional

This retrospective cohort study aims to investigate the effects of recombinant human growth hormone (rh-GH) on the euploid status of preimplantation blastocysts in AMA patients. Infertile patients aged 38-46 years old were recruited for study if they fulfill the inclusion criteria and do not have the exclusion criteria. Treatment group: Women received growth hormone (GH) supplement during antagonist protocol for ovarian stimulation. Control group: Women received antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts per stimulation cycle and per testing cycle.

NCT ID: NCT05447208 Recruiting - Growth Hormone Clinical Trials

Effect of GH on the Blastocyst Euploid Rate in AMA Patients

Start date: August 1, 2022
Phase: Phase 3
Study type: Interventional

This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement. Infertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Treatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation. Control group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.

NCT ID: NCT04079010 Completed - Clinical trials for Blood Flow Restriction

The Effect of Blood Flow Restriction With and Without Arginine on Physical Performance and Growth Hormone

Start date: September 4, 2019
Phase: N/A
Study type: Interventional

The current study will investigate the effects of Blood Flow Restriction (BFR) training and L-arginine supplementation on recreationally trained female participants. In particular, it will compare performance outcomes and blood markers among two intervention groups (BFR and BFR+Arg) and a control group (CON).

NCT ID: NCT01540773 Completed - Growth Hormone Clinical Trials

Single Low-Dose of Supplement Amino Acid

Start date: October 2011
Phase: N/A
Study type: Interventional

The purpose of the study is to confirm the results of a prior study that demonstrated pills containing two amino acids which are in foods increased growth hormone and insulin-like growth factor-1.

NCT ID: NCT01158612 Completed - Elderly Clinical Trials

The Effect of Local Injectet GH on the Collagen Synthesis in the Ligamentum Patella

Start date: August 2010
Phase: N/A
Study type: Interventional

Tendon and ligament injuries are a frequent problem among athletes but also in the general population. The healing process is a prolonged process, and complete recovery of tissue strength is nearly never reached. The purpose of this study is to examine the effect of local injection of human Growth Hormone on tendon collagen synthesis.

NCT ID: NCT00966134 Completed - Healthy Clinical Trials

Ghrelin, Growth Hormone and Growth Factors at High Altitude

Start date: April 2002
Phase: N/A
Study type: Observational

Regulation of ghrelin, growth hormone and growth factors at high altitude and their change during ascent to high altitude has not been studied in depth yet. The study includes 33 volunteers (12f) investigated at sea level, 4 days after ascent to 3440m and 14 days after ascent to 5400-5900m. The investigators hypothesized that during ascent growth hormone levels would increase to compensate for the higher energy needs at high altitude.

NCT ID: NCT00562796 Completed - Obesity Clinical Trials

Prevalence and Cardiovascular Effects of Growth Hormone Deficiency in Abdominal Obesity

Start date: November 2007
Phase: N/A
Study type: Observational

Obesity is one of the leading causes of cardiovascular-related diseases, including diabetes and heart disease. Obesity, and more specifically abdominal obesity, may cause decreased growth hormone (GH) levels. It is believed that GH deficiency may contribute to increased cardiovascular risk by affecting insulin resistance, inflammatory markers, and blood cholesterol levels. This study will determine the occurrence of GH deficiency in abdominal obesity and whether GH deficiency is associated with increased cardiovascular risk beyond traditional risk factors.